Johnson & Johnson Innovation (JLABS) Korea Innovation QuickFire Challenge: Targeting Neuroscience

Innovation challenge seeking ideas for transformative potential solutions that aim to address challenging, hard-to-drug targets relevant to neurodegeneration of the brain and eye and/or neuropsychiatry.

‘Johnson & Johnson Innovation – JLABS’ is a global innovation network that provides a range of support to accelerate the development of innovative, early stage startups in the life sciences sector, focusing on medical technology (MedTecH), pharmaceuticals and integrated healthcare solutions. JLABS operates across eleven international sites and brings together access to venture capital investment, incubation facilities, expertise, industry connections and entrepreneurial programmes to support early stage enterprises commercialising innovations in health technologies and the life sciences.

The JLABS QuickFire Challenge is an crowdsourcing innovation platform that sets innovation challenges to seek solutions for various medical, healthcare technology and other life sciences topics to deliver breakthroughs in healthcare ideas from innovators across the globe.

This Korea Innovation QuickFire Challenge – Targeting Neuroscience – is inviting submissions from innovators, including those from Korea and elsewhere in the world with a demonstrated interest in leveraging the Korea ecosystem, who are seeking to develop transformative potential solutions that aim to address challenging, hard-to-drug targets relevant to neurodegeneration of the brain and eye and/or neuropsychiatry.

The challenge aligns with the objective of Johnson & Johnson to help reduce the burden, disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases and its commitment to advancing understanding of these conditions and developing breakthrough treatments and solutions for people living with them.

Proposed solutions can be at any stage – including ideation, prototyping, piloting, and commercial launches – and should have a clear path to commercialisation (ie not just academic or basic research that is not pursuing a viable potential solution).

Potential solutions must demonstrate clear feasibility and proof of concept for the technology, with the potential for drug development and therapeutic benefits for individuals living with Alzheimer’s disease, Parkinson’s disease, geographic atrophy, schizophrenia, major depressive disorder and/or bipolar disorder

Proposed solutions can be at any stage – including ideation, prototyping, piloting, and commercial launches – and should have a clear path to commercialisation (ie not just academic or basic research that is not pursuing a viable potential solution).